# FEND for TB supplement to accelerate BLINK X development

> **NIH NIH U01** · RBHS-NEW JERSEY MEDICAL SCHOOL · 2022 · $218,451

## Abstract

ABSTRACT
The goal of this supplement is to perform assay development, optimization and analytic assessments of the
BLINK ONE, a novel tuberculosis identification and drug resistance testing system, potentially suitable for point
of care assessment of all known anti-tuberculosis drugs. This project will help develop a new way to easily test
for many genetic mutations in a single test using a simple device that could be used at the point of care. When
applied to tuberculosis, most types of drug resistance could be easily and rapidly diagnosed. This could vastly
simplify treatment decisions and potentially save hundreds of thousands of lives.

## Key facts

- **NIH application ID:** 10631415
- **Project number:** 3U01AI152084-03S1
- **Recipient organization:** RBHS-NEW JERSEY MEDICAL SCHOOL
- **Principal Investigator:** David Alland
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $218,451
- **Award type:** 3
- **Project period:** 2020-06-04 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10631415

## Citation

> US National Institutes of Health, RePORTER application 10631415, FEND for TB supplement to accelerate BLINK X development (3U01AI152084-03S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10631415. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*